Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer

Clinical Genitourinary Cancer

Volumn 11, Issue 2, 2013, Pages 175-181

  Galsky, Matthew D ^a,b   Hahn, Noah M ^c   Powles, Thomas ^d   Hellerstedt, Beth A ^a,e   Lerner, Seth P ^f   Gardner, Thomas A ^g   Yu, Menggang ^c   O'Rourke, Mark ^a,h   Vogelzang, Nicholas J ^a,i   Kocs, Darren ^a,e   McKenney, Scott A ^a,e   Melnyk, Anton M ^a,e   Hutson, Thomas E ^a,e   Rauch, Mary ^a   Wang, Yunfei ^a   Asmar, Lina ^a   Sonpavde, Guru ^a,e,f  

^a McKesson Specialty Health   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e TEXAS ONCOLOGY   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Cancer Centers of the Carolinas   (United States)

ⁱ Division of Hematology Oncology   (United States)

Author keywords

Antiangiogenic therapy; Chemotherapy; Hematologic toxicity; Neoadjuvant; Phase II

Indexed keywords

CISPLATIN; GEMCITABINE; SUNITINIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEMATURIA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; MALE; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NAUSEA; NEUTROPENIA; PREOPERATIVE CARE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; ULCER; VOMITING;

EID: 84876982362     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.10.001     Document Type: Article

References (33)

1. P.J. Loehrer Sr, L.H. Einhorn, P.J. Elson A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
2. C.J. Logothetis, F.H. Dexeus, L. Finn A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
3. A.O. Siefker-Radtke, R.E. Millikan, S.M. Tu Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer J Clin Oncol 20 2002 1361 1367
4. C.N. Sternberg, P.H. de Mulder, J.H. Schornagel Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924 J Clin Oncol 19 2001 2638 2646
5. C.N. Sternberg, A. Yagoda, H.I. Scher Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium J Urol 133 1985 403 407
6. A. Bamias, G. Aravantinos, C. Deliveliotis Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 22 2004 220 228
7. J. Bellmunt, H. Von der Maase, G.M. Mead Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup study Proc Am Soc Clin Oncol 25 2007 abstract 5030
8. R. Dreicer, J. Manola, B.J. Roth Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Cancer 100 2004 1639 1645
9. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
10. C.L. Vale Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202 206 discussion 5-6
11. B.H. Bochner, R.J. Cote, N. Weidner Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1995 1603 1612
12. A.J. Dickinson, S.B. Fox, R.A. Persad Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas Br J Urol 74 1994 762 766
13. T.M. Jaeger, N. Weidner, K. Chew Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer J Urol 154 1995 69 71
14. D.K. Chopin, J.P. Caruelle, M. Colombel Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine J Urol 150 1993 1126 1130
15. M. Nguyen, H. Watanabe, A.E. Budson Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients J Natl Cancer Inst 85 1993 241 242
16. K. Inoue, J.W. Slaton, D.W. Davis Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel Clin Cancer Res 6 2000 2635 2643
17. K. Inoue, M. Chikazawa, S. Fukata Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder Clin Cancer Res 8 2002 2389 2398
18. K. Inoue, M. Chikazawa, S. Fukata Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma Clin Cancer Res 9 2003 886 899
19. G. Bergers, S. Song, N. Meyer-Morse Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 2003 1287 1295
20. R. Erber, A. Thurnher, A.D. Katsen Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2004 338 340
21. J. Bellmunt, J.L. González-Larriba, C. Prior Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity Ann Oncol 22 2011 2646 2653
22. D.J. Gallagher, M.I. Milowsky, S.R. Gerst Phase II study of sunitinib in patients with metastatic urothelial cancer J Clin Oncol 28 2010 1373 1379
23. G. Sonpavde, W. Jian, H. Liu Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model Urol Oncol 27 2009 391 399
24. C.Y. Yoon, J.S. Lee, B.S. Kim Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells Korean J Urol 52 2011 55 63
25. M. Reck, N. Frickhofen, S. Cedres Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study Lung Cancer 70 2010 180 187
26. G. Griffiths, R. Hall, R. Sylvester International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
27. H.B. Grossman, R.B. Natale, C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
28. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
29. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
30. S. Postel-Vinay, C. Gomez-Roca, L.R. Molife Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 29 2011 1728 1735
31. N.M. Hahn, W.M. Stadler, R.T. Zon Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75 J Clin Oncol 29 2011 1525 1530
32. T.K. Choueiri, R.W. Ross, S. Jacobus Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol 30 2012 507 552
33. P. Grivas, D. Nanus, W. Stadler Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC) J Clin Oncol 30 suppl 5 2012 abstract 265